Option Care Health Soars 33% on $5.8 Billion Buyout by CD&R and McKesson: “A Great Outcome”
Option Care Health (OPCH) shares rose 33% after agreeing to a $5.8B buyout by CD&R and McKesson (MCK) at $32.05 per share, a 37% premium. The deal, expected to close in 2027, includes a path for McKesson to acquire CD&R's stake later. Option Care withdrew guidance and will not hold a Q3 earnings call.
How this was made
The 30-second read
Why it matters
The acquisition creates a vertically integrated platform for home‑based care, potentially improving margins and market reach.
Market read
The $5.8 B transaction is a material M&A event in the U.S. healthcare sector, driving immediate price action and shaping future industry dynamics.
What to watch
Potential integration challenges and the $1.4 B cash outlay for McKesson could strain balance sheets.
Background
Option Care Health (OPCH) is a home‑infusion provider; CD&R is a private‑equity firm; McKesson (MCK) is a large healthcare distributor.
Ticker impact
Option Care Health announced a $5.8 B cash buyout by CD&R and McKesson, sending the stock up 33% on the news.
limited upside, potential pressure as the market prices in the acquisition premium
Share price is already near the offer; any delay or failure could push it back toward pre‑deal levels.
McKesson is a co‑buyer in the $5.8 B acquisition of Option Care Health, committing $1.4 B for a 49% stake.
moderate upside as the market values the strategic expansion
Strategic fit and cash‑flow neutral financing suggest a favorable impact on McKesson's outlook.
Market effects
Consolidation in the home‑infusion and specialty pharmacy sector may pressure peers.
U.S. healthcare M&A activity receives a boost, potentially lifting related stocks.
Large‑scale deal underscores continued private‑equity interest in U.S. health services.
Counterpoint
If regulatory approval stalls, the stock could fall sharply below the offer price.
Key entities
- TargetOption Care Health
Home‑infusion provider being acquired.
- Private‑Equity SponsorCD&R
Acquires 51% stake in the deal.
- AcquirerMcKesson
Invests $1.4 B for a 49% stake and may buy the remaining shares later.
